Loading...
•
Jun 30
Boston Scientific Q2 2025 Earnings Report
Boston Scientific reported strong revenue and profit growth in Q2 2025.
Key Takeaways
Boston Scientific delivered a strong Q2 2025 with revenue surpassing $5 billion, driven by significant growth in the Cardiovascular segment. GAAP net income more than doubled year-over-year, and adjusted EPS exceeded guidance.
Revenue grew 22.8% year-over-year to $5.06 billion.
GAAP net income rose to $797 million, more than doubling from last year.
Cardiovascular organic revenue grew 23.2%, leading all segments.
U.S. revenue surged 30.7%, driving overall geographic performance.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope, Middle East & Africa Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.comLatin America & Canada Revenue
CapyFin.comEmerging Markets Revenue
CapyFin.com Forward Guidance
Boston Scientific expects continued strong growth in 2025, with double-digit revenue expansion and higher adjusted EPS.
Positive Outlook
- Full-year revenue growth expected at 18-19% reported and 14-15% organic.
- Adjusted EPS guidance raised to $2.95–$2.99 for FY2025.
- Q3 revenue expected to grow 17-19% reported and 12-14% organic.
- Cardiovascular segment continues to drive strong organic growth.
- Successful acquisitions expanding treatment portfolio.
Challenges Ahead
- Currency fluctuations expected to negatively impact reported growth by ~0.5%.
- Integration of acquisitions may add short-term costs.
- Restructuring charges expected to continue in 2025.
- Regulatory changes such as EU MDR may increase compliance costs.
- Emerging Markets growth remains moderate compared to U.S.
Revenue & Expenses
Visualization of income flow from segment revenue to net income